Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area

BackgroundMongolia has the highest mortality rate of gastric cancer. The early detection of cancer and down-staging screening for high risk patients are essential. Therefore, we aimed to validate serum markers for stratifying patients for further management.MethodsEndoscopy and histological examination were performed to determine high risk and gastric cancer patients. Rapid urease test, culture and histological tests were performed to diagnose Helicobacter pylori infection. Serum pepsinogen (PG) I and II and anti-H. pylori IgG were measured by ELISA. Receiver Operating Characteristic analysis was used to extract the best cut-off point.ResultsTotally 752 non-cancer and 50 consecutive gastric cancer patients were involved. The corpus chronic gastritis (72%: 36/50 vs. 56.4%: 427/752), corpus atrophy (42.0%: 21/50 vs. 18.2%: 137/752) and intestinal metaplasia (IM) (64.0%: 32/50 vs. 21.5%: 162/752) were significantly higher in gastric cancer than non-cancer patients, respectively. Therefore, corpus chronic gastritis, corpus atrophy and IM were considered as high risk disease. The best serum marker to predict the high risk status was PGI/II

背景 蒙古国胃癌死亡率最高。癌症的早期检测以及对高危患者进行降期筛查至关重要。因此，我们旨在验证血清标志物，以便对患者进行分层以进一步管理。 方法 进行内镜检查和组织学检查以确定高危患者和胃癌患者。进行快速尿素酶试验、培养和组织学试验以诊断幽门螺杆菌感染。通过酶联免疫吸附测定法测量血清胃蛋白酶原（PG）I和II以及抗幽门螺杆菌IgG。采用受试者工作特征分析来提取最佳截断点。 结果 共纳入752名非癌症患者和50名连续的胃癌患者。胃癌患者的胃体慢性胃炎（72%：36/50对比56.4%：427/752）、胃体萎缩（42.0%：21/50对比18.2%：137/752）和肠化生（IM）（64.0%：32/50对比21.5%：162/752）分别显著高于非癌症患者。因此，胃体慢性胃炎、胃体萎缩和肠化生被视为高危疾病。预测高危状态的最佳血清标志物是PGI/II